April 2024
1. 
   Pretreatment Characteristics of Carcinoid Tumors of the Lung Which Predict Aggressive Behavior: Erratum.
   Am J Clin Oncol. 2024;47:e1.
   

   >> Share

   
   
2. LIU X, Shen Q, Wen Y, Jiang Z, et al
   Diagnosis of Malignant Pulmonary Nodules Using a Combination of Tumor-associated Autoantibodies and Computed Tomography.
   Am J Clin Oncol. 2024;47:149-154.
   

   >> Share

   
   January 2024
3. CHOU B, Lee JH, Saetern L, Venkatesulu BP, et al
   Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy.
   Am J Clin Oncol. 2024 Jan 9. doi: 10.1097/COC.0000000000001077.
   

   >> Share

   
   December 2023
4. BRASCHI EL, Morris CG, Yeung AR, De Leo AN, et al
   Impact of Maximum Point Dose Within the Planning Target Volume on Local Control of Nonsmall Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.
   Am J Clin Oncol. 2023 Dec 25. doi: 10.1097/COC.0000000000001081.
   

   >> Share

   
   November 2023
5. ALVAREZ CM, Aliru M, Gannavarapu BS, Song T, et al
   Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in Non-Small Cell Lung Cancer.
   Am J Clin Oncol. 2023 Nov 24. doi: 10.1097/COC.0000000000001053.
   

   >> Share

   
   
6. YANG L, Lu X, Luo J, Huang D, et al
   Hyperfractionated Accelerated Radiotherapy Versus Stereotactic Body Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer: A Matched-Pair Analysis.
   Am J Clin Oncol. 2023 Nov 20. doi: 10.1097/COC.0000000000001066.
   

   >> Share

   
   
7. CANTRELL JN, Acharya P, Vesely SK, Gunter TC, et al
   Pathologic Nodal Staging Before SBRT for Early-stage NSCLC Does Not Impact Overall Survival: A Propensity Score-matched NCDB Analysis.
   Am J Clin Oncol. 2023;46:503-511.
   

   >> Share

   
   October 2023
8. ZHAO KX, Zhang YF, Zheng L, Pan YF, et al
   A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation.
   Am J Clin Oncol. 2023 Oct 2. doi: 10.1097/COC.0000000000001047.
   

   >> Share

   
   September 2023
9. YU S, Zhai S, Gong Q, Xiang C, et al
   Neoadjuvant Immunotherapy and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
   Am J Clin Oncol. 2023 Sep 26. doi: 10.1097/COC.0000000000001046.
   

   >> Share

   
   
10. ACIKGOZ Y, Yildirim FU, Esen SA, Ucar G, et al
    The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Sep 13. doi: 10.1097/COC.0000000000001044.
    

    >> Share

    
    August 2023
11. ZHU Z, Zhang A
    Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Aug 25. doi: 10.1097/COC.0000000000001035.
    

    >> Share

    
    July 2023
12. GARCIA-FUMERO R, Fernandez-Lopez C, Calleja-Hernandez MA, Exposito-Ruiz M, et al
    Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020.
    Am J Clin Oncol. 2023 Jul 31. doi: 10.1097/COC.0000000000001031.
    

    >> Share

    
    June 2023
13. LI F, Lv Q, Zhao S, Guo T, et al
    Prognostic Value of Pretreatment Serum Carcinoembryonic Antigen Level in 1130 Patients With Non-small Cell Lung Cancer: A Propensity Score Matching Cohort Study and Cumulative Mate-analysis.
    Am J Clin Oncol. 2023 Jun 27. doi: 10.1097/COC.0000000000001022.
    

    >> Share

    
    April 2023
14. YANG H, Li D, Liu T
    Prognostic Relevance of Negative Lymph Node Count in Resected Stage I-IIIa Small-cell Lung Cancer.
    Am J Clin Oncol. 2023 Apr 27. doi: 10.1097/COC.0000000000001006.
    

    >> Share

    
    
15. NIEDER C, Haukland EC, Mannsaker B, Dalhaug A, et al
    The LabPS score: Inexpensive, Fast, and Site-agnostic Survival Prediction.
    Am J Clin Oncol. 2023;46:178-182.
    

    >> Share

    
    March 2023
16. AFSHARI S, Anker CJ, Kooperkamp HZ, Sprague BL, et al
    Trends and Outcomes of Salvage Lobectomy for Early-stage Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Mar 24. doi: 10.1097/COC.0000000000001001.
    

    >> Share

    
    
17. ASHA W, Koro S, Mayo Z, Yang K, et al
    Stereotactic Body Radiation Therapy for Sarcoma Pulmonary Metastases.
    Am J Clin Oncol. 2023 Mar 14. doi: 10.1097/COC.0000000000001000.
    

    >> Share

    
    February 2023
18. HU YX, Guo LJ, Lin MQ, Lin QY, et al
    Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Feb 20. doi: 10.1097/COC.0000000000000985.
    

    >> Share

    
    
19. SAEED NA, Jin L, Amini A, Verma V, et al
    Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer.
    Am J Clin Oncol. 2023;46:66-72.
    

    >> Share

    
    January 2023
20. DELUCE J, Maj D, Verma S, Breadner D, et al
    Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis.
    Am J Clin Oncol. 2023 Jan 20. doi: 10.1097/COC.0000000000000976.
    

    >> Share

    
    December 2022
21. YANG H, Liu T, Li M, Fang Z, et al
    Does Examined Lymph Node Count Influence Survival in Surgically Resected Early‑stage Pulmonary Typical Carcinoid Tumors?
    Am J Clin Oncol. 2022;45:506-513.
    

    >> Share

    
    November 2022
22. HINOJOS M, Li X, Mikesell S, Studden S, et al
    Impact of Low-dose Chest CT Screening on the Association Between Rurality and Lung Cancer Outcomes.
    Am J Clin Oncol. 2022 Nov 3. pii: 00000421-990000000-00045.
    

    >> Share

    
    May 2022
23. RUAN T, Jiang P, Li C, Pan G, et al
    A Proposal to Modify the 8th IASLC System: Is it Suitable for T4N2M0 Lung Adenocarcinoma to Be Placed in Stage IIIB?
    Am J Clin Oncol. 2022;45:215-222.
    

    >> Share

    
    April 2022
24. JANG JK, Atay SM, Ding L, David EA, et al
    Patterns of Use of Stereotactic Body Radiation Therapy Compared With Surgery for Definitive Treatment of Primary Early-stage Non-small Cell Lung Cancer.
    Am J Clin Oncol. 2022;45:146-154.
    

    >> Share

    
    March 2022
25. BRYANT AK, Yin H, Schipper MJ, Paximadis PA, et al
    Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for Stage III Nonsmall-cell Lung Cancer.
    Am J Clin Oncol. 2022 Mar 11. pii: 00000421-900000000-98496.
    

    >> Share

    
    
26. KUBICEK GJ, Khrizman P, Squillante C, Callahan K, et al
    Stereotactic Body Radiotherapy and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer: Single Arm Phase 2 Study.
    Am J Clin Oncol. 2022;45:129-133.
    

    >> Share

    
    
27. MACBETH F, Treasure T
    The Biology and Systemic Treatments Influence Survival in Advanced Gastrointestinal Cancers While the Controlled Trial of Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) Found That Surgical Resection Could Only Have a Small If Any Effect.
    Am J Clin Oncol. 2022;45:135-136.
    

    >> Share

    
    January 2022
28. LIU J, Bratton E, Yu X, Ladbury C, et al
    Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
    Am J Clin Oncol. 2022 Jan 6. pii: 00000421-900000000-98513.
    

    >> Share

    
    
29. BURNS S, Vella M, Paciorek A, Zhang L, et al
    Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis.
    Am J Clin Oncol. 2022;45:22-27.
    

    >> Share

    
    November 2021
30. DURU BIRGI S, Akgun Z, Hurmuz P, Akyurek S, et al
    Definitive Chemoradiotherapy Results in Synchronous Oligometastatic Non-small Cell Lung Cancer Patients: Turkish Society for Radiation Oncology Group Study (TROD 10-003).
    Am J Clin Oncol. 2021 Nov 30. pii: 00000421-900000000-98519.
    

    >> Share

    
    
31. YOSHIMURA N, Sawa K, Nakai T, Matsumoto Y, et al
    Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2021 Nov 10. pii: 00000421-900000000-98525.
    

    >> Share

    
    October 2021
32. RITTBERG R, Banerji S, Kim JO, Rathod S, et al
    Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer.
    Am J Clin Oncol. 2021 Oct 11. pii: 00000421-900000000-98528.
    

    >> Share

    
    September 2021
33. WILLIAMS NR, Treasure T, Macbeth F, Fallowfield L, et al
    The Prospective Observational Cohort and the Nested Randomized Controlled Trial in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC Study) Question the Reliance on Existing Evidence for the Magnitude of Benefit From Lung Metastasectomy.
    Am J Clin Oncol. 2021;44:502-503.
    

    >> Share

    
    
34. AMIN M, Gao F, Terrero G, Picus J, et al
    Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Am J Clin Oncol. 2021;44:443-448.
    

    >> Share

    
    August 2021
35. BATRA A, Yusuf D, Hurry M, Walton RN, et al
    A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2021 Aug 11. pii: 00000421-900000000-98537.
    

    >> Share

    
    
36. YURKIEWICZ IR, Zhou M, Ganjoo KN, Charville GW, et al
    Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course.
    Am J Clin Oncol. 2021;44:419-422.
    

    >> Share

    
    June 2021
37. MORTMAN KD, Devlin J, Giang B, Mortman R, et al
    Patient Adherence in an Academic Medical Center's Low-dose Computed Tomography Screening Program.
    Am J Clin Oncol. 2021;44:264-268.
    

    >> Share

    
    May 2021
38. TUMINELLO S, Petralia F, Veluswamy R, Wang P, et al
    Prognostic Value of the Tumor Immune Microenvironment for Early-stage, Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2021 May 19. pii: 00000421-900000000-98563.
    

    >> Share

    
    
39. ROH J, Eom JS, Lee MK, Kim J, et al
    Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study.
    Am J Clin Oncol. 2021 May 17. pii: 00000421-900000000-98562.
    

    >> Share

    
    
40. YANG W, Zhang Y, Xia D, Xu X, et al
    The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
    Am J Clin Oncol. 2021;44:224-225.
    

    >> Share

    
    March 2021
41. PARSAI S, Sedor G, Smile TD, Scott J, et al
    Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic Sarcoma.
    Am J Clin Oncol. 2021;44:126-130.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share